Document Detail


Induced pluripotent stem cell research: A revolutionary approach to face the challenges in drug screening.
MedLine Citation:
PMID:  22370779     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Discovery of induced pluripotent stem (iPS) cells in 2006 provided a new path for cell transplantation and drug screening. The iPS cells are stem cells derived from somatic cells that have been genetically reprogrammed into a pluripotent state. Similar to embryonic stem (ES) cells, iPS cells are capable of differentiating into three germ layers, eliminating some of the hurdles in ES cell technology. Further progress and advances in iPS cell technology, from viral to non-viral systems and from integrating to non-integrating approaches of foreign genes into the host genome, have enhanced the existing technology, making it more feasible for clinical applications. In particular, advances in iPS cell technology should enable autologous transplantation and more efficient drug discovery. Cell transplantation may lead to improved treatments for various diseases, including neurological, endocrine, and hepatic diseases. In studies on drug discovery, iPS cells generated from patient-derived somatic cells could be differentiated into specific cells expressing specific phenotypes, which could then be used as disease models. Thus, iPS cells can be helpful in understanding the mechanisms of disease progression and in cell-based efficient drug screening. Here, we summarize the history and progress of iPS cell technology, provide support for the growing interest in iPS cell applications with emphasis on practical uses in cell-based drug screening, and discuss some challenges faced in the use of this technology.
Authors:
Minjung Song; Saswati Paul; Hyejin Lim; Ahmed Abdal Dayem; Ssang-Goo Cho
Related Documents :
10834979 - Role of vaca and caga in helicobacter pylori inhibition of mucin synthesis in gastric m...
2093009 - Role of gastrin as a trophic hormone.
3111919 - Influence of the prostaglandin e1 analogue rioprostil on the human gastric mucosa.
8888719 - Omeprazole produces parietal cell hypertrophy and hyperplasia in humans.
20809749 - Lentiviral vector-mediated upregulation of let-7a inhibits gastric carcinoma cell growt...
2320939 - Non-steroidal anti-inflammatory drugs and gastric dna synthesis.
6113889 - Role of asparaginase synthetase and asparagyl-transfer rna synthetase in the cell-killi...
2458359 - Two independent mechanisms for escaping epidermal growth factor-mediated growth inhibit...
22154859 - Cell death in hela mediated by thermoplastic polyurethane with co-immobilized ifn-γ pl...
Publication Detail:
Type:  Journal Article     Date:  2012-02-28
Journal Detail:
Title:  Archives of pharmacal research     Volume:  35     ISSN:  0253-6269     ISO Abbreviation:  Arch. Pharm. Res.     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-02-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8000036     Medline TA:  Arch Pharm Res     Country:  Korea (South)    
Other Details:
Languages:  eng     Pagination:  245-60     Citation Subset:  IM    
Affiliation:
Department of Animal Biotechnology, Animal Resources Research Center, and SMART-IABS, Konkuk University, Seoul, 143-701, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Oncogenic challenges in stem cells and the link to cancer initiation.
Next Document:  Humanized murine model for HBV and HCV using human induced pluripotent stem cells.